EGRF and PAR2 Regulation of Intestinal Permeability

The present invention provides a method of treating an autoimmune disease, comprising the steps of increasing transepithelial electrical resistance leading to decreased cell permeability. Further provided is ajnethod of treating celiac disease in an individual in need of such treatment, comprising the steps of: administering an antibody directed against single chain zonulin thereby inhibiting epidermal growth factor receptor and inhibiting PAR2.

Patents:
WO 2,010,144,140   [MORE INFO]

Inventor(s): FASANO ALESSIO [US]; LAMMERS KAREN [US]; SHEA-DONOHUE TEREZ [US]

Type of Offer: Licensing



« More Medical Patents

---